Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management.

Andres Ramirez-Gamero Humberto Martínez-Cordero Brady Ernesto Beltrán-Gárate Jorge A Florindez Luis E Malpica-Castillo Jorge J Castillo

Published in: American journal of hematology (2024)

Combination chemotherapy regimens, such as EPOCH, are recommended. The addition of bortezomib, lenalidomide, or daratumumab might improve outcomes. Including PBL patients and their participation in prospective clinical trials is warranted.

Keyphrases

newly diagnosed
multiple myeloma
clinical trial
end stage renal disease
ejection fraction
chronic kidney disease
physical activity
prognostic factors
squamous cell carcinoma
diffuse large b cell lymphoma
type diabetes
adipose tissue
insulin resistance
skeletal muscle
study protocol
open label